Research Topics
Species | J D WolchokSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanomaJ Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Oncol 23:viii15-21. 2012..Further research is warranted to establish how immunotherapeutic agents can be combined with conventional agents, with each other or with molecularly targeted agents such as vemurafenib, to further optimise clinical outcomes...
Defining the critical hurdles in cancer immunotherapyBernard A Fox
Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
J Transl Med 9:214. 2011..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanomaJedd D Wolchok
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Melanoma Res 13:189-96. 2003..The observation of two partial responses has led to a phase II study to evaluate treatment with high dose paracetamol alone or in combination with BCNU...
Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigensJ D Wolchok
The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Immun 1:9. 2001..These results show that immunity to TRP-2 following DNA immunization uses an IFN-gamma-dependent Th1 pathway, but immunity to gp75/TRP-1 is down-regulated by IFN-gamma...
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanomaJedd D Wolchok
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 15:2044-50. 2007..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
Current topics in melanomaJedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Curr Opin Oncol 19:116-20. 2007..New approaches to melanoma are emerging. This review summarizes developments over the past 12 months...
Reassessing the usual suspects causing a commotion in the blood (and vessels?)Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer Biol Ther 3:124-5. 2004
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activationJedd D Wolchok
Melanoma Sarcoma Oncology Service and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 340, New York, New York 10065, USA
Oncologist 13:2-9. 2008....
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaJedd D Wolchok
Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 15:7412-20. 2009..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyJedd D Wolchok
Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Lancet Oncol 11:155-64. 2010..Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma...
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York 10021, USA
Cancer Immun 10:9. 2010..These findings support the hypothesis that ipilimumab-treated patients with advanced melanoma have similar outcomes regardless of their HLA-A*0201 status...
Multiple pathways to tumor immunity and concomitant autoimmunityMary Jo Turk
1Weill Graduate School of Medical Sciences of Cornell University, New York, USA
Immunol Rev 188:122-35. 2002..Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer...
Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogsC A Manley
Donaldson Atwood Cancer Clinic, The Animal Medical Center, New York, NY, USA
J Vet Intern Med 25:94-9. 2011..Metastatic disease is a common sequela for which few effective treatment options exist. Studies show that xenogeneic tyrosinase DNA vaccination yields immune responses and prolongation of survival in dogs with oral malignant melanoma...
Coupling and uncoupling of tumor immunity and autoimmunityW B Bowne
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Exp Med 190:1717-22. 1999..e., antibody versus CD8(+) T cell. However, both pathways led to tumor immunity and identical phenotypic manifestations of autoimmunity...
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanomaJianda Yuan
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY, USA
Cancer Immun 9:5. 2009..One patient had an increase in CD8+ IFN-gamma+ cells. This xenogeneic immunization strategy was safe and associated with minimal toxicity. There was also evidence of immune response...
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanomaJack C F Liao
Flaherty Comparative Oncology Laboratory, Donaldson-Atwood Cancer Clinic, The Animal Medical Center, New York, NY 10021, USA
Cancer Immun 6:8. 2006..Most interestingly, the onset of antibody induction in these three dogs coincides with observed clinical responses and may suggest a means to account for their long-term tumor control and survival...
Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantationRobert R Jenq
Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Blood 113:1574-80. 2009..In conclusion, our data suggest that KGF can function as a potent vaccine adjuvant after allo-BMT through its effects on posttransplantation T-cell reconstitution...
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injectionBrian A Ginsberg
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
Clin Cancer Res 16:4057-65. 2010..To further define the optimal vaccination strategy, we conducted a pilot clinical trial comparing i.m. injection with particle-mediated epidermal delivery (PMED)...
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanomaYvonne M Saenger
The Swim Across America Laboratory, Immunology Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer Res 68:9884-91. 2008..Monoclonal antibodies should be tested as vaccine adjuvants in the treatment of cancer...
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domainsCristina R Ferrone
The Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, Weill Medical and Graduate Schools of Cornell University, New York, NY 10021, USA
Clin Cancer Res 12:5511-9. 2006....
Development of effective vaccines for old mice in a tumor modelDavid N Posnett
Dep of Medicine, Weill Medical College of Cornell University, New York, NY 10021, United States
Vaccine 27:1093-100. 2009..However, fusion constructs with Vp22 gave a strong CD4 response to B16 melanoma and the OmpA response is MHC-II dependent. Both adjuvant fusion constructs stimulated CD4 and CD8 responses otherwise diminished in old mice...
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefitJianda Yuan
Ludwig Center for Cancer Immunotherapy, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Proc Natl Acad Sci U S A 105:20410-5. 2008..These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade...
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanomaMiguel Angel Perales
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 16:2022-9. 2008..Responding T cells had an effector memory cell phenotype. Polyfunctional T cells were also demonstrated. At a median of 31 months follow-up, median survival has not been reached. Human GM-CSF DNA was found to be a safe adjuvant...
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II studyWen Jen Hwu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 103:2590-7. 2005..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccineFrancesca Orlandi
Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 13:6195-203. 2007..HER2/neu is frequently overexpressed in breast cancer. In a mouse model, vaccination with HER2/neu DNA elicits antibodies that confer partial protection against tumor challenge...
Mechanisms of immunization against cancer using chimeric antigensManuel E Engelhorn
The Swim Across America Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Ther 16:773-81. 2008..Therefore large fusion vector panels such as those presented here can provide information to promote the successful advancement of gene-based vaccines...
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune responseGabrielle A Rizzuto
Departments of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Exp Med 206:849-66. 2009..Further, precursor frequency as an isolated variable can be exploited to augment efficacy of clinical vaccine strategies designed to activate any antigen-specific CD8(+) T cells...
DNA vaccines: an active immunization strategy for prostate cancerJedd D Wolchok
Clinical Immunology Services, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Semin Oncol 30:659-66. 2003..We are currently conducting a phase I trial of human and mouse PSMA DNA vaccines in patients with recurrent prostate cancer, based on preclinical experiments described below...
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trialPhilip J Bergman
Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The E and M Bobst Hospital of the Animal Medical Center, New York, New York 10021, USA
Clin Cancer Res 9:1284-90. 2003..These studies provided the rationale for a trial of xenogeneic DNA vaccination in CMM using the human tyrosinase gene...
Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopesColin S B Houghton
The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
Vaccine 25:5330-42. 2007..These data demonstrate that this approach can serve as the basis of epitope-engineering against cancer and intracellular pathogens...
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulationAdam D Cohen
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 5:e10436. 2010..These findings provide further support for the continued development of agonist anti-GITR mAbs as an immunotherapeutic strategy for cancer...
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunityTeresa Ramirez-Montagut
Memorial Sloan-Kettering Cancer Center and the Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Oncogene 22:3180-7. 2003..Vitiligo (autoimmune hypopigmentation) can be mediated by T cells, FcgammaR+macrophages and/or complement...
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigenJason S Gold
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Immunol 170:5188-94. 2003....
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanomaWen Jen Hwu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Cancer 106:2445-51. 2006..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
Vaccines for melanoma: translating basic immunology into new therapiesJ D Wolchok
Clinical Immunology Service, Hematologic Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY 10021, USA
Lancet Oncol 2:205-11. 2001..Although initial clinical trials have shown the safety and immunological efficacy of vaccines for melanoma, the true clinical benefit of these strategies will only be revealed in large randomised trials...
Phase II trial of neoadjuvant temozolomide in resectable melanoma patientsG D Shah
Department of Medicine, Sloan Kettering Cancer Center, New York, NY, USA
Ann Oncol 21:1718-22. 2010..A secondary objective was to test the feasibility of obtaining adequate tissue before and after treatment for genetic testing...
Optimization of a self antigen for presentation of multiple epitopes in cancer immunityJose A Guevara-Patino
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Clin Invest 116:1382-90. 2006....
Phase II study of extended-dose temozolomide in patients with melanomaPetra Rietschel
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Clin Oncol 26:2299-304. 2008..We hypothesized that expression of methylguanine methyltransferase (MGMT) in the tumor would correlate with drug resistance to TMZ...
Stage-IV melanoma and pulmonary metastases: factors predictive of survivalHeather B Neuman
Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H1221, New York, New York 10021, USA
Ann Surg Oncol 14:2847-53. 2007..We reviewed a contemporary, single-institution experience to evaluate the natural history of stage-IV melanoma metastatic to the lung and identify factors predictive of survival...
Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancersDavid B Page
Melanoma Sarcoma Service, Memorial Sloan Kettering Cancer Center, NY, USA
Immunotherapy 2:367-79. 2010..The immunogram - a newly described graphical synthesis of treatment data and immune correlates in individual patients - may help us to confirm, reject or formulate new hypotheses regarding the mechanism of anti-CTLA-4 activity...
Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogueRoopa Srinivasan
Swim Across America Laboratory and Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Medical College and Graduate School of Cornell University, New York, NY 10021, USA
Cancer Immun 2:8. 2002..This represents an example of intermolecular determinant recognition, but is not simply due to epitope spreading since antibodies against the antigen targeted by DNA vaccination are not typically detected...
The role of lipopolysaccharide in T-cell responses following DNA vaccinationWilliam G Hawkins
Swim Across America Laboratory, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Vaccine 21:1548-53. 2003..CD8(+) T-cell responses were readily induced in TLR4-deficient mice immunized with DNA depleted of LPS. LPS in DNA vaccines is not required for CD8(+) T-cell responses...
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responsesYun Lin
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, Newy York, New York 10021, USA
Cytotherapy 11:912-22. 2009..Monitoring cellular immune responses is one prerequisite for the rational development of cancer vaccines...
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoringJ Yuan
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cytotherapy 8:498-508. 2006..This HLA-matched APC line can be adapted to other HLA haplotypes, and has advantages for monitoring clinical trials of immunotherapy with limited availability of autologous APC and PBMC from patients...
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanomaWen Jen Hwu
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:3351-6. 2003..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapyMargaret K Callahan
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Semin Oncol 37:473-84. 2010..Several immunologic endpoints have been proposed to correlate with clinical activity. This review will focus on the endpoints of immune monitoring described in studies to date and discuss future areas of additional work needed...
Melanoma vaccinesMiguel Angel Perales
Clinical Immunology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford I Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Cancer Invest 20:1012-26. 2002..In this review, we will discuss strategies to induce active immunity against melanoma...
Radiotherapy after surgical resection for head and neck mucosal melanomaAbraham J Wu
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
Am J Clin Oncol 33:281-5. 2010..To present our single-institution experience with postoperative radiotherapy for mucosal melanoma of the head and neck...
DNA vaccines against cancerRodica Stan
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Hematol Oncol Clin North Am 20:613-36. 2006..It gives a brief history and then discusses the proposed mechanism of action, preclinical and clinical studies, and methods of enhancing the immune responses induced by DNA vaccines...
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyJianda Yuan
Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, New York, NY 10065, USA
Cancer Immun 10:1. 2010..The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters...
Immune rejection of mouse tumors expressing mutated selfFei Duan
Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Cancer Res 69:3545-53. 2009..Immune modulation, such as inducing GITR signaling, is required to enhance CD8(+) T-cell responses to specific mutations and to lead to tumor rejection...
Immunity to cancer through immune recognition of altered self: studies with melanomaJose A Guevara-Patino
Memorial Sloan Kettering Cancer Center and the Weill Graduate School of Medical Sciences and Medical School of Cornell University, 1275 York Avenue, New York, NY 10021, USA
Adv Cancer Res 90:157-77. 2003..Studies examining the molecular basis for immunogenicity of conserved paralogues are facilitating the development of new strategies to rationally design vaccines that trigger adaptive immune responses to cancer...
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccinationPolly D Gregor
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Int J Cancer 116:415-21. 2005..These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth...
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphomaMaria Lia Palomba
Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:370-9. 2005..These results show that active immunization with xenogeneic DNA vaccines can induce CD8+ T cell-dependent immunity against CD20...
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunityAdam D Cohen
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Res 66:4904-12. 2006..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves...
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemiaPeter G Maslak
Leukemia Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Blood 116:171-9. 2010..Further studies are needed to establish the role of vaccination as viable postremission therapy for acute myeloid leukemia...
DNA vaccines for melanomaAdam D Cohen
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
Cancer Chemother Biol Response Modif 22:761-8. 2005
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantationMiguel Angel Perales
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Immunol 177:4159-67. 2006..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged swordAlan N Houghton
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Cell 7:403-5. 2005..These are surprising observations, linking antibodies of the adaptive immune system to innate immune responses that drive epithelial carcinogenesis...
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systemsPolly D Gregor
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Vaccine 22:1700-8. 2004..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformaticsNeil H Segal
Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Immun 5:2. 2005....
Antigens recognized by autologous antibodies of patients with soft tissue sarcomaNeil H Segal
Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cancer Immun 5:4. 2005..Further studies of these selected novel STS antigens are warranted to identify and characterize potential antigen targets expressed by STS...
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21Govind Ragupathi
Laboratory of Tumor Vaccinology, Clinic Immunology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:5214-20. 2003..However, vaccination of patients with GD2-KLH has previously failed to induce a consistent relevant antibody response. We test here whether the use of GD2 lactone-KLH can overcome the low immunogenicity of GD2-KLH...
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient casesYvonne M Saenger
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Cancer Immun 8:1. 2008..Understanding the kinetics of response to ipilimumab will help clinicians to manage patients who may benefit from treatment. In this article, several cases that illustrate the kinetics of response to ipilimumab are discussed...
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particlesStacie M Goldberg
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 11:8114-21. 2005..The purpose of this study was to compare viral and plasmid DNA in combination vaccination strategies in the context of a tumor antigen...
Clinical results using biochemotherapy as a standard of care in advanced melanomaP B Chapman
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, NY 10021, USA
Melanoma Res 12:381-7. 2002..The low response rate among previously treated patients indicates that biochemotherapy is not useful as second-line therapy...
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical CenterP J Bergman
Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA
Vaccine 24:4582-5. 2006..These studies provided the impetus for development of a xenogeneic DNA vaccine program in CMM...
Persistence makes perfect: the benefits of IL-2 in adoptive immunotherapyG A Rizzuto
Swim Across America Laboratory of Tumor Immunology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
Cytotherapy 7:391-2. 2005
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profilingNeil H Segal
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 21:1775-81. 2003..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implicationsY B Su
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 22:610-6. 2004..CONCLUSION: TMZ at this dose and schedule results in CD4(+) lymphopenia in a majority of patients that can result in OIs. Pneumocystis pneumonia prophylaxis should be considered for patients who develop sustained lymphopenia on TMZ...
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccinesMiguel Angel Perales
The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Cytokines Cell Mol Ther 7:125-33. 2002..These results have implications for understanding early events in the immune response to DNA vaccines, and provide a basis for development of new approaches to cancer vaccines, including the use of cytokine genes as adjuvants...
Immune regulatory antibodies: are they the next advance?Jedd D Wolchok
Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Cancer J 16:311-7. 2010....
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosisDaniel Hirschhorn-Cymerman
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Exp Med 206:1103-16. 2009..Closer examination revealed that diminished intratumoral T reg cell levels resulted from hyperactivation and T reg cell-specific apoptosis. Thus, we propose that CTX and OX40 engagement represents a novel and rational chemoimmunotherapy...
Anti-GITR antibodies--potential clinical applications for tumor immunotherapyDavid A Schaer
Memorial Sloan Kettering Cancer Center, Department of Medicine, 1275 York Avenue, New York, NY 10065, USA
Curr Opin Investig Drugs 11:1378-86. 2010..This review discusses the role of GITR as a potential target for immunomodulatory therapy, as well as the research involved in understanding the mechanisms of anti-GITR therapy and current progress in translation into the clinic...
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitopeJedd D Wolchok
J Clin Oncol 20:3176; author reply 3176-7. 2002
How can we tell when cancer vaccines vaccinate?Jedd D Wolchok
J Clin Oncol 21:586-7. 2003
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapyHoward L Kaufman
J Clin Oncol 24:2230-2. 2006
Strategies to overcome immune ignorance and toleranceMiguel Angel Perales
Memorial Sloan Kettering Cancer Center and Weill Medical School and Graduate School of Cornell University, New York, NY 10021, USA
Semin Cancer Biol 12:63-71. 2002..Crucial to these approaches is the discovery and understanding of the molecular identity of antigens and the mechanisms involved in tumor immunity. In this review, strategies to overcome immune ignorance and tolerance are discussed...
CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytesMiguel-Angel Perales
Ann Surg Oncol 11:881-2. 2004
Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literatureSteven C Katz
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Am J Surg 193:493-7. 2007..Melanoma has the potential to spread to virtually any organ, including the gallbladder. The role of intervention in this rare entity must be based on a thorough appreciation of the underlying disease biology...
Meeting report: fourth international congress of the Society for Melanoma ResearchDavid E Fisher
Department of Pediatric Hematology Oncology and Melanoma Program, Dana Farber Cancer Institute and Children s Hospital of Boston, Boston, MA 02115, USA
Pigment Cell Melanoma Res 21:15-26. 2008..This report will highlight the major scientific themes and advances of this most successful meeting, and provide a useful perspective on the current state of melanoma research, as well as where the field should be heading...
